Cyclopharm’s investor presentation: USFDA approval insights
Cyclopharm is pleased to provide shareholders access to our recent webinar presentation on October 5th, 2023. During this session, Cyclopharm discussed several significant developments, focusing on our recent USFDA approval.
USFDA approval highlights:
- Formal approval granted: On September 29, 2023, Cyclomedica received formal approval from the USFDA, marking a significant achievement in our journey.
- Tapping into a key market: The United States represents one of the largest nuclear medicine markets globally, offering substantial opportunities for Cyclomedica.
- Market potential: The potential market size for diagnosing Pulmonary Embolism with Technegas® Plus System in the USA exceeds US$180 million.
- Immediate rollout: We have swiftly initiated our product rollout in the USA to meet the growing demand.
- Expanding global presence: The USFDA approval extends our market reach to the 65th country, reinforcing our commitment to global expansion.
- Broad indication: Our approval includes a broad indication for “Visualisation of pulmonary ventilation,” providing increased versatility.
- Leveraging the US market: Access to the US market not only enhances our Technegas core business but also supports our broader aspirations in Beyond PE.
By offering the insights from this webinar, we aim to provide our shareholders with a thorough grasp of Cyclopharm’s strategic trajectory and the considerable prospects that await us. Please download the full presentation to gain a deeper understanding of the profound significance of the USFDA approval as Cyclopharm advances into the next phase of our strategic growth journey.